Successful treatment of psoriatic arthritis with rituximab

J D Cohen

Unité d’Immuno-Rhumatologie Clinique, Hôpital Lapeyronie, Montpellier, France

Correspondence to:
Jean David Cohen, Unité d’Immuno-Rhumatologie Clinique, Hôpital Lapeyronie, 191 av du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France; jd-cohen@chu-montpellier.fr

Accepted 7 February 2008

The first 150 words of the full text of this article appear below.

Rituximab is a chimeric human/mouse monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) refractory to anti-tumour necrosis factor (TNF) therapy.¹ Rituximab seems to be efficient in other diseases such as autoimmune cytopoenia,² systemic lupus erythaematosus (SLE),³ dermatomyositis⁴ and Sjögren syndrome.⁵ To our knowledge, no case of psoriatic arthritis (PsA) treated by rituximab has been reported. Nevertheless, a partial remission of psoriasis following rituximab therapy for non-Hodgkin’s lymphoma has been reported.⁶ We describe the case of a man with severe PsA with dramatic improvement after rituximab treatment.

A 62-year-old Caucasian male had PsA since 2001 with asymmetrical arthritis involving distal interphalangeal arthritis, wrist, knee and ankle joint, and dactylitis. He has a personal (15 years ago) and familial history of psoriasis. Antibodies to cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) were negative, human leukocyte antigen (HLA) typing gave HLA A1 A24 B7 B8 DRB1*03 DRB1*15 DQB1*02 DQB1*06. . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• ATZENI, F., SARZI-PUTTINI, P., VENA, G. A. (2009). Resistant Cases of Psoriatic Arthritis: How to Manage Them. The Journal of Rheumatology Supplement 83: 73-75 [Abstract] [Full Text]